CL2013000518A1 - Uso de 2r,3s-dihidromiricetina para preparar un medicamento util para tratar, inhibir y/o reducir la intoxicacion con etanol, un sintoma del sindrome de abstinencia alcoholica, trastornos del uso o abuso del alcohol y/o alcohol y/o alcoholismo en un sujeto. - Google Patents

Uso de 2r,3s-dihidromiricetina para preparar un medicamento util para tratar, inhibir y/o reducir la intoxicacion con etanol, un sintoma del sindrome de abstinencia alcoholica, trastornos del uso o abuso del alcohol y/o alcohol y/o alcoholismo en un sujeto.

Info

Publication number
CL2013000518A1
CL2013000518A1 CL2013000518A CL2013000518A CL2013000518A1 CL 2013000518 A1 CL2013000518 A1 CL 2013000518A1 CL 2013000518 A CL2013000518 A CL 2013000518A CL 2013000518 A CL2013000518 A CL 2013000518A CL 2013000518 A1 CL2013000518 A1 CL 2013000518A1
Authority
CL
Chile
Prior art keywords
alcohol
dihydromyricetin
alcoholism
abuse
symptom
Prior art date
Application number
CL2013000518A
Other languages
English (en)
Spanish (es)
Inventor
Jing Liang
Richard W Olsen
Igor Spigelman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2013000518A1 publication Critical patent/CL2013000518A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CL2013000518A 2010-08-24 2013-02-22 Uso de 2r,3s-dihidromiricetina para preparar un medicamento util para tratar, inhibir y/o reducir la intoxicacion con etanol, un sintoma del sindrome de abstinencia alcoholica, trastornos del uso o abuso del alcohol y/o alcohol y/o alcoholismo en un sujeto. CL2013000518A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37652810P 2010-08-24 2010-08-24

Publications (1)

Publication Number Publication Date
CL2013000518A1 true CL2013000518A1 (es) 2013-08-02

Family

ID=45724009

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000518A CL2013000518A1 (es) 2010-08-24 2013-02-22 Uso de 2r,3s-dihidromiricetina para preparar un medicamento util para tratar, inhibir y/o reducir la intoxicacion con etanol, un sintoma del sindrome de abstinencia alcoholica, trastornos del uso o abuso del alcohol y/o alcohol y/o alcoholismo en un sujeto.

Country Status (14)

Country Link
US (1) US20130053435A1 (enExample)
EP (1) EP2608786A2 (enExample)
JP (1) JP2013536238A (enExample)
KR (1) KR20130098347A (enExample)
CN (1) CN103269699A (enExample)
AU (1) AU2011293556A1 (enExample)
BR (1) BR112013003946A2 (enExample)
CA (1) CA2808680A1 (enExample)
CL (1) CL2013000518A1 (enExample)
EA (1) EA201390217A1 (enExample)
MX (1) MX2013002162A (enExample)
PH (1) PH12013500293A1 (enExample)
SG (1) SG187771A1 (enExample)
WO (1) WO2012027326A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
CN103772338A (zh) * 2014-01-10 2014-05-07 吉首大学 真空脉动式制备二氢杨梅素的方法
MX2020010545A (es) * 2018-04-06 2021-01-08 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias.
CN108567772A (zh) * 2018-07-24 2018-09-25 广西师范大学 二氢杨梅素的新用途
CN113260359A (zh) * 2018-11-05 2021-08-13 伊万涅姆医疗保健股份有限公司 酒精解毒剂
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
KR20220012903A (ko) * 2019-05-23 2022-02-04 이케이와이제이 컨설팅 투 엘엘씨 알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법
GR1010117B (el) 2020-07-14 2021-11-08 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος
CN112546014B (zh) * 2020-12-15 2023-01-31 铜仁职业技术学院 一种中药解酒护肝泡腾片及其制备方法
CN113842461B (zh) * 2021-11-04 2023-08-11 杭州诺莘科技有限责任公司 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293825C (zh) * 2002-08-30 2007-01-10 广州拜迪生物医药有限公司 二氢杨梅树皮素在制备食品、化妆品或药品中的应用
KR20040021927A (ko) * 2002-09-06 2004-03-11 차재영 호깨나무와 홍삼 추출물을 이용한 건강 보조식품프로헤파-알지의 개발
CN101336978B (zh) * 2008-08-12 2013-01-30 西北农林科技大学 一种北枳椇总黄酮的提取方法
CN101336987B (zh) * 2008-08-12 2012-04-25 西北农林科技大学 一种枳椇总黄酮的制备方法

Also Published As

Publication number Publication date
SG187771A1 (en) 2013-03-28
MX2013002162A (es) 2013-04-05
EP2608786A4 (en) 2013-07-03
AU2011293556A1 (en) 2013-02-28
US20130053435A1 (en) 2013-02-28
WO2012027326A2 (en) 2012-03-01
WO2012027326A9 (en) 2012-04-19
EA201390217A1 (ru) 2013-12-30
CN103269699A (zh) 2013-08-28
BR112013003946A2 (pt) 2016-07-12
EP2608786A2 (en) 2013-07-03
JP2013536238A (ja) 2013-09-19
PH12013500293A1 (en) 2013-03-25
CA2808680A1 (en) 2012-03-01
KR20130098347A (ko) 2013-09-04

Similar Documents

Publication Publication Date Title
CL2013000518A1 (es) Uso de 2r,3s-dihidromiricetina para preparar un medicamento util para tratar, inhibir y/o reducir la intoxicacion con etanol, un sintoma del sindrome de abstinencia alcoholica, trastornos del uso o abuso del alcohol y/o alcohol y/o alcoholismo en un sujeto.
She et al. On the structure of the multigranulation rough set model
BR112015001465A2 (pt) item tendo propriedades armazenamento e/ou descarga de líquido, em particular um curativo.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
FI20095800A0 (fi) Nonwoven komposiittituote, jolla on korkea selluloosapitoisuus
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2013002357A1 (es) Articulo para fumar, que comprende una mezcla de tabaco con bajo contenido de tsa y/o metales, y un carbono de alta actividad derivado de polimero sintetico.
CL2013000261A1 (es) Compuestos derivados de heterociclos nitrogenados, con actividad ampk; composicion farmaceutica; metodos in vitro; y su uso en enfermedades cardiovasculares, diabetes tipo ii, distrofia muscular, trastornos neurolgicos, enfermedades inflamatorias, entre otras.
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
CL2013001411A1 (es) Peptido que posee actividad antiapoptotica; conjugado que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o condicion asociada con apoptosis en un sujeto.
CL2015001681A1 (es) Unidad solida con alto contenido en fexofenadina; procedimiento de preparacion; y uso de la misma como antihistaminico, broncodilatador y/o para el tratamiento de alergias y/o urticarias.
DK2900788T3 (da) Robust bindingsmiddel som er uden påvirkning af katalytisk aktive stoffer, til anvendelse i råolie- og naturgasindustrien
BR112012028533A2 (pt) cateter e seu uso, método para iniciar pleurodese e método para irritar ou enrugar uma superfície
CL2013000962A1 (es) Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas.
Radenović et al. Common fixed points for (g, f) type maps in cone metric spaces
Zhao et al. The finite-dimensional super integrable system of a super NLS-mKdV equation
Antonsen Čállinmeattáhusaid guorran
ARTEGIANI What Determines the Capital Structure of Companies in the Epra/Nareit Europe Index? A Comparison before and after the Global Financial Crisis
赵丽荣 Can you come to my party?
Sang-soo A Study on the Identity of Four Municipalities in China
周霜 Functional Discourse Analysis of Twitter News
Sinvuttaya BOOK REVIEW: THE POLITICAL THINKING OF JACQUES RANCIÉRE